Obesity Drug Wegovy Cut Risk of Serious Heart Problems by 20%, Study Finds

November 13, 2023by Jonel Aleccia, Associated Press
Obesity Drug Wegovy Cut Risk of Serious Heart Problems by 20%, Study Finds
This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy medication. (Novo Nordisk via AP)

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.

The research is the first to document that an obesity medication can not only pare pounds, but also safely prevent a heart attack, stroke or a heart-related death in people who already have heart disease — but not diabetes.

The findings could shift perceptions that the new class of obesity drugs are cosmetic treatments and put pressure on health insurers to cover them.

“It moves from a kind of therapy that reduces body weight to a therapy that reduces cardiovascular events,” said Dr. Michael Lincoff, the study’s lead author and a heart expert at the Cleveland Clinic.

Wegovy is a high-dose version of the diabetes treatment Ozempic, which already has been shown to reduce the risk of serious heart problems in people who have diabetes. The new study looked to see if the same was true in those who don’t have that disease.

Experts have known for years that losing weight can improve heart health, but there hasn’t been a safe and effective obesity medication proven to reduce specific risks, said Dr. Francisco Lopez-Jimenez, a heart expert at the Mayo Clinic. He expects the new findings to change treatment guidelines and “dominate the conversation” for years to come.

“This is the population who needs the medicine the most,” said Lopez-Jimenez, who had no role in the study.

In the U.S., there are about 6.6 million people like those tested in the study, experts said.

The results were published Saturday in the New England Journal of Medicine and presented at a medical conference in Philadelphia. Novo Nordisk, the maker of Wegovy and Ozempic, has asked the U.S. Food and Drug Administration to include the heart benefits on Wegovy’s label, like on Ozempic’s.

The new study, paid for by the company, included more than 17,500 people in 41 countries. Participants were age 45 and older, had a body mass index of 27 or higher and were tracked for more than three years on average. They took typical drugs for their heart conditions, but they were also randomly assigned to receive weekly injections of Wegovy or a dummy shot.

The study found that 569, or 6.5%, of those who got the drug versus 701, or 8%, of those who received the dummy shot had a heart attack or stroke or died from a heart-related cause. That’s an overall reduction of 20% in the risk of those outcomes, the researchers reported.

The drop appeared to be fueled primarily by the difference in heart attacks, but the number of serious health complications reported were too small to tell whether the individual outcomes were caused by the drug or by chance.

Study volunteers who took Wegovy lost about 9% of their weight while the placebo group lost less than 1%.

The Wegovy group also saw drops in key markers of heart disease, including inflammation, cholesterol, blood sugars, blood pressure and waist circumference, noted Dr. Martha Gulati, a heart expert at Cedars-Sinai Medical Center in Los Angeles. Changes in those markers began early in the study, before participants lost much weight.

“It means to me that it’s more than just weight loss, how this drug works,” said Gulati, who had no role in what she called a landmark study.

Still, “it remains unclear” how much of the results were a benefit of losing weight or the drug itself, an editorial accompanying the study noted.

About a third of all study volunteers reported serious side effects. About 17% in the Wegovy group and about 8% in the comparison group left the study, mostly because of nausea, vomiting, diarrhea and other stomach-related problems.

Nearly three-quarters of participants were men and nearly 84% were white. Gulati and others said future research needs to include more women and racial and ethnic minorities.

Wegovy is part of a new class of injectable medications for obesity. On Wednesday, the U.S. Food and Drug Administration approved Eli Lilly’s Zepbound, a version of the diabetes drug Mounjaro, for weight control.

Both carry high price tags — monthly costs are about $1,300 for Wegovy and about $1,000 for Zepbound. And both have been in shortage for months, with manufacturers promising to boost supplies.

The medications are often not covered by private health insurance or subject to strict preauthorization requirements. Medicare, the government health plan for older Americans, is prohibited from covering drugs for weight loss alone. But drugmakers and obesity treatment advocates have been pushing for broader coverage, including asking Congress to pass legislation to mandate that Medicare pay for the drugs.

Results from the latest study and others that show the obesity drugs have a direct effect on costly health problems could be a factor in shifting the calculus of coverage, said Dr. Mark McClellan, former chief of the Centers for Medicare and Medicaid Services and the FDA. In 2006, Medicare was allowed to cover weight-loss surgery to treat the complications of severe obesity, if not obesity itself, he noted.

That approach “may end up being relevant here,” he said.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

A+
a-

In The News

Health

Voting

Health

A Year After Jimmy Carter Entered Hospice Care, Advocates Hope His Endurance Drives Awareness

ATLANTA (AP) — Since Jimmy Carter entered hospice care at his home in south Georgia one year ago, the former U.S. president... Read More

ATLANTA (AP) — Since Jimmy Carter entered hospice care at his home in south Georgia one year ago, the former U.S. president has celebrated his 99th birthday, enjoyed tributes to his legacy and lost his wife of 77 years. Rosalynn Carter, who died in November, about six months after the Carter... Read More

February 20, 2024
by Jesse Zucker
The Impact of Human Connection on Your Health

WASHINGTON —  As we trudge through the winter, months of cold and dreary weather may sap our desire to go... Read More

WASHINGTON —  As we trudge through the winter, months of cold and dreary weather may sap our desire to go outside and socialize. While it’s normal to isolate sometimes, chronic isolation can increase loneliness and be detrimental to your mental and physical health.  Scrolling on social... Read More

February 20, 2024
by Jesse Zucker
Everything You Need to Know About Protein

WASHINGTON — There is a lot of misinformation in the world of nutrition. Macronutrients and calories get demonized while magical... Read More

WASHINGTON — There is a lot of misinformation in the world of nutrition. Macronutrients and calories get demonized while magical supplements promise to help you lose weight. Thankfully, protein stays strong throughout all the wild trends — and for good reason. If you’ve ever been told... Read More

February 14, 2024
by Dan McCue
New York City Sues Social Media Platforms for ‘Fueling’ Mental Health Crisis

NEW YORK — The city of New York and its health and education departments sued five social media platforms on... Read More

NEW YORK — The city of New York and its health and education departments sued five social media platforms on Wednesday, saying they need to be held accountable for fueling a mental health crisis among youths across the nation. The announcement of the lawsuit against TikTok,... Read More

February 14, 2024
by Dan McCue
COVID Vax, Booster During Pregnancy Bolsters Protections for Newborns

WASHINGTON — Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with significant protection... Read More

WASHINGTON — Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with significant protection against COVID-19 for at least six months after birth, a new study found. The research was conducted by the Infectious Diseases Clinical Research Consortium and published... Read More

Mental Health Emerges as Dividing Line in Abortion Rights Initiatives Planned for State Ballots

CHICAGO (AP) — The weeks after Kaniya Harris found out she was pregnant were among the hardest in her life.... Read More

CHICAGO (AP) — The weeks after Kaniya Harris found out she was pregnant were among the hardest in her life. Final exams were fast approaching for the college junior. Her doctors told her she had an ovarian cyst, and the risk of ectopic pregnancy was high.... Read More

News From The Well
scroll top